On Monday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $2.31 which represents a slight increase of $0.15 or 6.94% from the prior close of $2.16. The stock opened at $2.3 and ...
Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
Cantor Fitzgerald reiterated their overweight rating on shares of Alector (NASDAQ:ALEC – Free Report) in a research report ...
BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9.Don't Miss our Black Friday Offers:Unlock ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
Alector (NASDAQ:ALEC – Free Report) had its target price lowered by BTIG Research from $16.00 to $5.00 in a research note ...
Alector Inc (ALEC) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.27 and touched a low of $2.06 ...
"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...